Abstract
General anesthesia-induced pharmacological protection of the central nervous system following injury has been under intense investigations during the past four decades. Indeed, if general anesthetics could provide therapeutic benefit in the event of hypoxia, ischemia or any other kinds of brain lesions, that would be of tremendous clinical importance. The potential for anesthesia-related brain protection, however, has been seriously challenged during the past 10 years. In fact, an increasing number of experimental and, more recently, clinical observations suggest that general anesthetics might exert unwanted, toxic effects on the brain especially when administered to young infants or to the elderly. Of utmost importance, recent data suggest that these same drugs could even have therapeutic effects in some psychiatric disorders. The goal of this review is to highlight these apparent contradictions. We will consider the available experimental evidence arguing for anesthetic-induced neuroprotection and highlight the lack of clinical studies supporting this notion. The biological rational for anesthesia neurotoxicity will then be explored together with existing experimental and clinical evidence in favor of this possibility. Finally, insights into the increasing number of both experimental and clinical data suggesting that general anesthetics, especially ketamine, support the therapeutic value of these drugs in major depressive disorders. When taken together, these seemingly contradictory observations suggest the intriguing possibility that general anesthetics could stand as valuable context-dependent modulators of neural plasticity.
Keywords: Brain, general anesthesia, neuroprotection, neurotoxicity, plasticity.
Current Pharmaceutical Design
Title:General Anesthetics in Brain Injury: Friends or Foes?
Volume: 20 Issue: 26
Author(s): Laszlo Vutskits
Affiliation:
Keywords: Brain, general anesthesia, neuroprotection, neurotoxicity, plasticity.
Abstract: General anesthesia-induced pharmacological protection of the central nervous system following injury has been under intense investigations during the past four decades. Indeed, if general anesthetics could provide therapeutic benefit in the event of hypoxia, ischemia or any other kinds of brain lesions, that would be of tremendous clinical importance. The potential for anesthesia-related brain protection, however, has been seriously challenged during the past 10 years. In fact, an increasing number of experimental and, more recently, clinical observations suggest that general anesthetics might exert unwanted, toxic effects on the brain especially when administered to young infants or to the elderly. Of utmost importance, recent data suggest that these same drugs could even have therapeutic effects in some psychiatric disorders. The goal of this review is to highlight these apparent contradictions. We will consider the available experimental evidence arguing for anesthetic-induced neuroprotection and highlight the lack of clinical studies supporting this notion. The biological rational for anesthesia neurotoxicity will then be explored together with existing experimental and clinical evidence in favor of this possibility. Finally, insights into the increasing number of both experimental and clinical data suggesting that general anesthetics, especially ketamine, support the therapeutic value of these drugs in major depressive disorders. When taken together, these seemingly contradictory observations suggest the intriguing possibility that general anesthetics could stand as valuable context-dependent modulators of neural plasticity.
Export Options
About this article
Cite this article as:
Vutskits Laszlo, General Anesthetics in Brain Injury: Friends or Foes?, Current Pharmaceutical Design 2014; 20 (26) . https://dx.doi.org/10.2174/13816128113196660652
DOI https://dx.doi.org/10.2174/13816128113196660652 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: How Drugs may Work to Better Protect the Gastrointestinal Tract: Mechanisms Involved in Gastrointestinal Tract Protection]
Current Pharmaceutical Design Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Necessity for Re-Vascularization after Spinal Cord Injury and the Search for Potential Therapeutic Options
Current Neurovascular Research Kinins as Therapeutic Agents in Cardiovascular and Renal Diseases
Current Pharmaceutical Design The Potential of Hydrogen for Improving Mental Disorders
Current Pharmaceutical Design Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Randomized Clinical Stroke Trials in 2006
Current Vascular Pharmacology Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design Mechanisms of Antihistamines and Mast Cell Stabilizers in Ocular Allergic Inflammation
Medicinal Chemistry Reviews - Online (Discontinued) Pharmacokinetic Changes of Drugs in Rat Model of Acute Renal Failure Induced by Uranyl Nitrate: Correlation Between Drug Metabolism and Hepatic Microsomal Cytochrome P450 Isozymes
Current Clinical Pharmacology Potential Role of Natural Compounds Against Skin Aging
Current Medicinal Chemistry The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies
Current Molecular Medicine Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets Clinical Evidence of Intravitreal Triamcinolone Acetonide in the Management of Age-Related Macular Degeneration
Current Drug Targets The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Natural Substances in the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Brain Tumor Detection from MR Images Employing Fuzzy Graph Cut Technique
Recent Advances in Computer Science and Communications